RE:Non optimized vs optimized Very encouraging. 25% of the first 12 underdosed patients were CR at 90 days. Keytruda only achieved 41% at 90 days and just 19% at one year and this was enough for FDA approval. At a bare minimum TLD1433 will achieve twice this number of CR patients and likely many more than that. It's looking very good for FDA approval and very significant stock price appreciation.
enriquesuave wrote: 1st 12 patients undertreated by 39-85% yielded a 25% CR or 3 patients at 90 days
6 optimized treated patients yielded 67% or 4 out of 6 patients and maybe would have been 5 as one patient died after negative urinate cytology.
Hence Optimized is about 2-4 Times as likely to get CR at 90 days. IMO